| Autor: |
Youjia Zhong, Amuthavalli Kottaiswamy, Chen Xiang Ang, Hui’ En Li, Gaik Chin Yap, Carina J. X. Tay, Nurul Elyana Osman, Siti Namirah Binte Roslan, Chee Wah Tan, Wee Chee Yap, Elizabeth Y. Ang, Pauline P. L. Chan Ng, Hui Kim Yap, Liangjian Lu, Marion M. Aw, Sivaraman V. Karthik, Seng Hock Quak, Thuan Chong Quah, Elizabeth H. Tham, Lynette P. Shek, Eng Eong Ooi |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Frontiers in Immunology, Vol 15 (2024) |
| Druh dokumentu: |
article |
| ISSN: |
1664-3224 |
| DOI: |
10.3389/fimmu.2024.1502598 |
| Popis: |
BackgroundIn endemic COVID-19, immunocompromised children are vulnerable until vaccinated but the optimal primary vaccination regime and need for booster doses remains uncertain.MethodsWe recruited 19 immunocompromised children (post-solid organ transplantation, have autoimmune disease or were on current or recent chemotherapy for acute lymphoblastic leukemia), and followed them from the start of primary vaccination with BNT162b2 mRNA SARS-CoV-2 until 1-year post-vaccination. We investigated the quality of vaccine immunogenicity, and longevity of hybrid immunity, in comparison to healthy children.ResultsImmunocompromised children failed to produce T cell and memory B cell (MBC) responses reaching thresholds of protection after 2 doses; a third dose however improved both responses. Initially robust hybrid immunity demonstrated significantly more decline in T cell and MBC responses in immunocompromised compared to healthy children, to levels below the protective threshold by month 12.DiscussionImmunocompromised children may benefit from a 3-dose primary vaccination regime, with yearly or twice-yearly booster doses for sustained immunity. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
